Japan’s digital therapeutics market is gaining momentum as aging, chronic disease demand, regulatory support, insurance coverage, AI and B2B partnerships accelerate adoption.

Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Japan Digital Therapeutics Market, till 2035: Industry Trends and Forecasts - Distribution by Type of Solution, Type of Therapy, Purpose of Solution, Type of Business Model and Target Therapeutic Area" has been added to ResearchAndMarkets.com's offering.

Japan Digital Therapeutics Market to Reach USD 1.13 Billion by 2035, Growing at a 23.6% CAGR

The Japan digital therapeutics market is projected to grow from USD 0.15 billion in 2026 to USD 1.13 billion by 2035, representing a compound annual growth rate (CAGR) of 23.6% during the 2026-2035 forecast period. Market expansion is being supported by healthcare digitization, an aging population, regulatory reforms, technological innovation, and increasing demand for effective chronic disease management.

Japan Digital Therapeutics Market Growth and Trends

Digital therapeutics are gaining momentum across Japan as healthcare providers, payers, employers, pharmaceutical companies, and technology developers increase their investment in clinically validated software solutions. These products support the prevention, treatment, and management of conditions such as metabolic disorders, cardiovascular diseases, mental health conditions, neurological disorders, chronic pain, sleep disorders, respiratory diseases, and substance use disorders.

Japan's rapidly aging population is a major driver of digital therapeutics market growth. More than 20% of the country's population is aged 65 or older, increasing the burden of diabetes, hypertension, cardiovascular disease, and other chronic conditions. Digital treatment platforms, remote monitoring technologies, and behavioral interventions can improve treatment adherence and facilitate care delivery across urban and rural communities.

Supportive regulatory developments are also accelerating market entry. Streamlined pathways for selected Software as a Medical Device products, combined with expanding national health insurance coverage for approved solutions, are creating a more favorable commercial environment. Integration with electronic health records and wider collaboration among hospitals, insurers, employers, pharmaceutical companies, and digital health developers are expected to strengthen adoption.

Advances in artificial intelligence, machine learning, connected devices, and wearable technologies are further enabling personalized interventions and real-time patient monitoring. These capabilities can support better clinical outcomes, generate actionable real-world evidence, and improve care management at both individual and population levels.

Market Challenges

Despite strong growth prospects, the Japan digital therapeutics market faces several barriers. National health insurance reimbursement remains limited to a relatively small number of approved products, which may restrict widespread adoption. Awareness among clinicians and patients also requires improvement, while data privacy concerns, cybersecurity requirements, personnel shortages, and complex reimbursement pathways continue to affect commercialization.

Future market growth will depend on coordinated progress across regulation, reimbursement, clinical validation, healthcare professional education, and technology infrastructure. Companies capable of demonstrating measurable clinical and economic value will be better positioned to secure partnerships and market access.

Metabolic Disorders Lead the Therapeutic Area Segment

Metabolic disorders currently account for approximately 25% of the Japan digital therapeutics market, followed by mental health conditions. The leading position of metabolic disorders is supported by their high prevalence, Japan's aging demographics, favorable regulatory developments, and growing demand for behavioral change and medication adherence solutions.

The market also covers cardiovascular disorders, chronic pain, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other therapeutic areas. Demand across these categories is expected to rise as healthcare organizations seek scalable and evidence-based approaches to disease management.

B2B Business Model Holds the Largest Market Share

The business-to-business model represents approximately 65% of the Japan digital therapeutics market. Its dominance is driven by partnerships involving healthcare facilities, insurers, employers, pharmaceutical companies, and technology developers. These collaborations support implementation, reimbursement integration, patient access, and broader commercial distribution. The business-to-consumer segment is also expected to develop as awareness and direct access to digital health services increase.

Key Japan Digital Therapeutics Market Segments

Solution type: Software solutions, gaming solutions, and combination solutions
Therapy type: Curative and preventive therapies
Purpose: Medication replacement and medication augmentation solutions
Business model: B2B and B2C
Therapeutic area: Cardiovascular disorders, chronic pain, mental health conditions, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other conditions

Key Questions Addressed in the Report

How many digital therapeutics developers are active in Japan?
Which companies are leading the Japan digital therapeutics market?
What trends, growth drivers, and opportunities are shaping the market?
What regulatory, reimbursement, operational, and adoption challenges affect market development?
What are the current and forecast values of the Japan digital therapeutics market?
How will market opportunities be distributed across major solution, therapy, business model, and therapeutic area segments?

Reasons to Purchase the Report

The report provides detailed revenue forecasts for the overall Japan digital therapeutics market and its principal subsegments. It evaluates market drivers, barriers, opportunities, competitive developments, customer demand, and emerging trends to help established companies and new entrants make informed strategic decisions.

Stakeholders can use the analysis to assess commercial opportunities, understand target audience requirements, develop market-entry strategies, strengthen customer engagement, and identify high-potential therapeutic areas. The report is designed to support pharmaceutical companies, digital health developers, investors, insurers, healthcare providers, consultants, and other organizations participating in Japan's expanding digital healthcare ecosystem.

Complementary Benefits

Excel data packs covering all analytical modules included in the report
Up to 15% complimentary content customization
A detailed report walkthrough with the research team
A complimentary update when the purchased report is six months old or older

Key Topics Covered:

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Digitization in Healthcare Sector
6.3. Next-Generation Healthcare Solutions
6.4. Key Concepts Associated with Digital Health Solutions
6.4.1. Cognitive Behavioral Therapy (CBT)
6.4.2. Internet of Things (IoT)
6.4.3. Big Data
6.4.4. Artificial Intelligence (AI)
6.4.5. Gamification
6.5. Overview of Digital Therapeutics
6.5.1. Key Strategic Initiatives
6.5.1.1. Digital Therapeutics Alliance (DTA)
6.5.1.2. Personal Connected Health (PCH) Alliance
6.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
6.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
6.5.1.5. National Health Service (NHS) Guidelines
6.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
6.5.2. Typical Development and Commercialization Path for Digital Therapeutics
6.5.2.1. Discovery and Preclinical Phase
6.5.2.2. Clinical Trials and Validation
6.5.2.3. Negotiation Involving Insurance Providers / Payers
6.5.2.4. Distribution and Marketing
6.6 Concluding Remarks

7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Japan Digital Therapeutics Market: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Business Model
7.2.5. Analysis by Type of Technology
7.2.6. Analysis by Purpose of Solution
7.2.7. Analysis by Target Population

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Japan Digital Therapeutics Developers: Company Competitiveness Analysis
8.4.1. Small Japan Digital Therapeutics Developers (Peer Group I)
8.4.2. Mid-sized Japan Digital Therapeutics Developers (Peer Group II)
8.4.3. Large Japan Digital Therapeutics Developers (Peer Group III)
8.5. Capability Benchmarking of top Japan Digital Therapeutics Developers

9. COMPANY PROFILES: JAPAN DIGITAL THERAPEUTICS MARKET
9.1. Chapter Overview
9.2. Susmed
9.2.1. Company Overview
9.2.2. Product Portfolio
9.2.3. Financial Information
9.2.4. Recent Developments and Future Outlook
9.3. CureApp
9.4. Hacarus
9.5. Ubie

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Japan Digital Therapeutic Solution Providers: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Most Active Players: Analysis by Number of Partnerships
10.3.4. Analysis by Geography
10.3.4.1. Intercontinental and Intracontinental Agreements
10.3.4.2. Local and International Agreements

11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion

12. JAPAN DIGITAL THERAPEUTICS MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Japan Digital Therapeutics Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
12.4. Roots Analysis Perspective on Market Growth
12.5 Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario
12.6. Key Market Segmentations

13. JAPAN DIGITAL THERAPEUTICS MARKET, BY TYPE OF SOLUTION
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Japan Digital Therapeutics Market: Distribution by Type of Solution
13.3.1. Japan Digital Therapeutics Market for Standalone Software Applications: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.3.2. Japan Digital Therapeutics Market for Combination Offerings focused on Software Application, Historical Trends (Since 2022) and Forecasted Estimates (Till 2025)
13.3.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach Historical Trends (Since 2022) and Forecasted Estimates (Till 2025)
13.3.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, Historical Trends (Since 2022) and Forecasted Estimates (Till 2025)
13.3.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), Historical Trends (Since 2022) and Forecasted Estimates (Till 2025)
13.3.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), Historical Trends (Since 2022) and Forecasted Estimates (Till 2025)
13.4. Data Triangulation and Validation

14. JAPAN DIGITAL THERAPEUTICS MARKET, BY PURPOSE OF SOLUTION
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Japan Digital Therapeutics Market: Distribution by Purpose of Solution
14.3.1. Japan Digital Therapeutics Market for Medication Replacement Solutions, Historical Trends (Since 2022) and Forecasted Estimates (Since 2022) and Forecasted Estimates (Till 2035)
14.3.2. Japan Digital Therapeutics Market for Medication Augmentation Solutions, Historical Trends (Since 2022) and Forecasted Estimates (Since 2022) and Forecasted Estimates (Till 2035)
14.4. Data Triangulation and Validation

15. JAPAN DIGITAL THERAPEUTICS MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Japan Digital Therapeutics Market: Distribution by Type of Therapy
15.3.1. Japan Digital Therapeutics Market for Curative Therapy, Historical Trends (Since 2022) and Forecasted Estimates (Since 2022) and Forecasted Estimates (Till 2035)
15.3.2. Japan Digital Therapeutics Market for Preventive Therapy, (Since 2022) and Forecasted Estimates (Till 2035)
15.4. Data Triangulation and Validation

16. JAPAN DIGITAL THERAPEUTICS MARKET, BY BUSINESS MODEL
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Japan Digital Therapeutics Market: Distribution by Business Model
16.3.1. Japan Digital Therapeutics Market for B2C Model, (Since 2022) and Forecasted Estimates (Since 2022) and Forecasted Estimates (Till 2035)
16.3.2. Japan Digital Therapeutics Market for B2B Model, (Since 2022) and Forecasted Estimates (Till 2035)
16.4. Data Triangulation and Validation

17. JAPAN DIGITAL THERAPEUTICS MARKET, BY THERAPEUTIC AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Japan Digital Therapeutics Market: Distribution by Therapeutic Area
17.3.2. Japan Digital Therapeutics Market for Cardiovascular Disorders (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3. Japan Digital Therapeutics Market for Chronic Pain, (Since 2022) and Forecasted Estimates (Till 2035)
17.3.4. Japan Digital Therapeutics Market for Mental Health Problems, (Since 2022) and Forecasted Estimates (Till 2035)
17.3.5. Japan Digital Therapeutics Market for Metabolic Disorders, (Since 2022) and Forecasted Estimates (Till 2035)
17.3.6. Japan Digital Therapeutics Market for Neurological Disorders, (Since 2022) and Forecasted Estimates (Till 2035)
17.3.7. Japan Digital Therapeutics Market for Respiratory Disorders, (Since 2022) and Forecasted Estimates (Till 2035)
17.3.8. Japan Digital Therapeutics Market for Sleep Disorders, (Since 2022) and Forecasted Estimates (Till 2035)
17.3.9. Japan Digital Therapeutics Market for Substance Use Disorders, (Since 2022) and Forecasted Estimates (Till 2035)
17.3.10. Japan Digital Therapeutics Market for Other Disorders, (Since 2022) and Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation

18. CONCLUDING REMARKS

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

A selection of companies mentioned in this report includes, but is not limited to:

Omega Healthcare Investors
Teladoc Health
ResMed
Fitbit
Mango Health
Akili
Hygeia Healthcare Holdings
DarioHealth
BioGaia

For more information about this report visit https://www.researchandmarkets.com/r/nsajro

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

Japan Digital Therapeutics Market Set for Strong Growth Through 2035, Driven by Innovative Solutions, Evolving Therapy Models and Expanding Opportunities Across Key Therapeutic Areas